Drug development

Advocating for Awareness and Empowerment: Jason Colodne and Colbeck Capital Sponsor the Children's Tumor Foundation NF Summit 2024

Retrieved on:

Tuesday, April 9, 2024

Colbeck Capital Management (“Colbeck”) today announced its ongoing support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the CTF NF Summit 2024, the largest educational gathering in the neurofibromatosis (“NF”) and schwannomatosis community.

Key Points:

Colbeck Capital Management (“Colbeck”) today announced its ongoing support of the Children’s Tumor Foundation (“CTF” or the “Foundation”) through sponsorship of the CTF NF Summit 2024, the largest educational gathering in the neurofibromatosis (“NF”) and schwannomatosis community.
This year’s summit includes a renewed focus on the role of patients and care advocates in advancing NF research, contributing to CTF’s goal of bringing new treatments to the market.
Supporters like Jason Colodne and Colbeck Capital have enabled CTF to continue driving research and awareness through innovative initiatives and events like the NF Summit.
More information regarding CTF and NF Summit 2024 can be found at https://www.ctf.org/ .

Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing

Retrieved on:

Monday, April 8, 2024

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.

Key Points:

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.
Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work.
In this week’s episode, Mr. Nathanielsz discusses the competitive advantage of the Company and its enzyme treatment for metastatic cancer.
Some key points to the competitive advantage highlighted by Mr. Nathanielsz include:
Global Financing Strategy: Mr. Nathanielsz emphasizes the company's global view on accessing funds and its current pursuit of series A financing, showcasing a strategic approach to securing financial support.

AffyImmune Therapeutics Announces Clinical and Regulatory Advisory Board to Support Development of AIC100 in Solid Tumors

Retrieved on:

Monday, April 8, 2024

The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.

Key Points:

The CRAB will provide strategic counsel and expertise as AffyImmune advances its affinity-tuned CAR T therapeutics in clinical development.
“This group of distinguished scientists and advisors bring to AffyImmune invaluable CAR T drug development experience from research to commercialization,” said Sonal Gupta, MD, PhD, AffyImmune SVP and Head of Clinical Development.
‘’I am honored to join Affylmmune’s Clinical and Regulatory Advisory Board and look forward to working with the other members to advance the development of novel treatments,” said Carmelo Nucera, MD, PhD.
Jorge J. Nieva, MD , Associate Professor of Clinical Medicine, Keck School of Medicine, University of Southern California and Section Head, Solid Tumors, USC/Norris Cancer Center.

Zura Bio Announces Robert Lisicki as CEO and Director

Retrieved on:

Monday, April 8, 2024

Biotechnology, Pharmaceutical, Health, Clinical Trials, Partnership, Drug development, Multimedia, Autoimmunity, Autoimmune disease, Inflammation, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.

Key Points:

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki has assumed the role of Chief Executive Officer and a Director of the Board at Zura Bio.
The Company previously announced Mr. Lisicki's appointment and the commencement of a seamless transition process with Founding CEO, Dr. Someit Sidhu.
"With a successful track record in strategy, commercial operations, and drug development, Robert is well suited to establish Zura Bio as a leading immunology company.
On behalf of the board, I would like to welcome Robert,” stated Amit Munshi, Chairman of Zura Bio Board of Directors.

Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Retrieved on:

Tuesday, April 9, 2024

Knowledge, Neurology, Acadia Pharmaceuticals, Pediatrics, CDKL5, Communication, RTT, Patient, FOXG1, Research, Disorder, Competitive landscape, Rett syndrome, Drug development, USFDA

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Key Points:

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.

Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Retrieved on:

Tuesday, April 9, 2024

Knowledge, Neurology, Acadia Pharmaceuticals, Pediatrics, CDKL5, Communication, RTT, Patient, FOXG1, Research, Disorder, Competitive landscape, Rett syndrome, Drug development, USFDA

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033

Key Points:

HARTFORD, Conn., April 9, 2024 /PRNewswire/ -- Thelansis Knowledge Partners, specialized in pharmaceutical and biopharmaceutical business research and consulting Company that provides data driven research and consulting support released highly valued Market Outlook Report Title: Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033
Rett Syndrome (RTT) is an orphan neurodevelopmental disorder for which no cure exists.
The condition is clinically heterogenous; key patient types include typical or classical RTT and atypical RTT.
Although the disorder is rare, it causes life-long impairment and severe symptoms requiring treatments such as antiepileptics and supportive therapies.
Only one drug is USFDA approved for the treatment of RTT: Daybue (trofinetide), which is marketed by Acadia Pharmaceuticals.

CURE OPENS XSEED AWARD APPLICATIONS TO SUPPORT UNDERFUNDED AND UNDERREPRESENTED NYC LIFE SCIENCE STARTUPS WITH UP TO $500,000

Retrieved on:

Tuesday, April 9, 2024

Xchange, Pharmacology, Health, Mentorship, NYCEDC, Health equity, Research, Female, Doctor of Philosophy, Faculty, NIH, Male, Syneos Health, MPH, Pediatrics, Drug development, Economic development, Cure, Nursing

Deerfield Management, a New York City-based healthcare investment firm, founded and supports the XSeed Award.

Key Points:

Deerfield Management, a New York City-based healthcare investment firm, founded and supports the XSeed Award.
The deadline for XSeed Award application submissions is May 31, 2024, and virtual finalist presentations will be June 28, 2024.
"Deerfield is pleased to continue our collaboration on the transformational XSeed program, alongside the NYCEDC, Cure and the experts who comprise our enthusiastic XSeed Award Leadership Committee."
"We look forward to welcoming the XSeed Award winners who, along with the Cure Xchange Challenge winners, are startups advancing health through collaboration and community building via Cure."

BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies

Retrieved on:

Tuesday, April 9, 2024

Molecule, AME Publishing Company, Development, Hepatocyte, Application, Travel, Running, Doctor of Philosophy, Senior, University of Oxford, ADME, Drug development, MPS

WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques, a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research. Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT. The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications. Please visit BioIVT's website for registration and additional details here.

Key Points:

WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques , a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research.
Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT.
The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications.
In addition to being the largest supplier of products for in vitro ADME studies, the company also will discuss the preclinical research services it offers, including designing and implementing in vitro ADME-Tox programs.

Cleveland Clinic's Dr. Matt Kalaycio Appointed Chair of Board of Directors for National Comprehensive Cancer Network

Retrieved on:

Monday, April 8, 2024

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.

Key Points:

PLYMOUTH MEETING, Pa., April 8, 2024 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
He is Vice-Chair of Cleveland Clinic Cancer Institute and a professor of medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
"As I take on the role of Chair of the NCCN Board of Directors, I eagerly anticipate further advancing the organization's mission."
"I am very honored to serve as the Vice-Chair of the NCCN Board of Directors," said Dr. Lieu.

Clinical Data Strategy in Action for Complex Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on:

Monday, April 8, 2024

Machine learning, Collection, Data management, Artificial intelligence, Acquisition, Clinical data management, Drug development, Medical imaging

TORONTO, April 8, 2024 /PRNewswire-PRWeb/ -- The need for more efficient, patient-centric approaches in drug development is ushering in a new era of innovative clinical trials such as master protocols and adaptive designs that enhance flexibility and accelerate the identification of effective treatments. While these novel approaches are vital tools for improving patient outcomes, especially within oncology and rare diseases, they significantly increase the complexity of data handling, from collection to analysis. This complexity mirrors a wider shift in clinical research towards a more data-rich environment drawing on a wider variety of emerging data sources.

Key Points:

The featured speakers will discuss how real-time access to data enhances operational efficiency and supports more informed strategic decision-making within complex trial designs.
Close alignment across clinical data functions provides a robust foundation that enhances adaptive capabilities, reduces data bottlenecks and inefficiencies and supports more informed, timely decision-making.
This webinar brings together clinical data experts from clinical data acquisition, data management and statistical analysis disciplines for an interactive conversation exploring the vital roles of technology, collaboration, and flexibility in navigating the complexities of today'sclinical trials.
Register for this webinar today to learn how a unified clinical data strategy, advanced clinical data technologies and real-time data access can streamline complex clinical trials.